AveXis Inc. (NASDAQ:AVXS) shares saw an uptick in trading volume on Thursday . 284,492 shares were traded during trading, an increase of 39% from the previous session’s volume of 204,773 shares.The stock last traded at $34.83 and had previously closed at $36.07.

A number of research firms recently commented on AVXS. Wells Fargo & Co. began coverage on AveXis in a research note on Friday. They set a “market perform” rating on the stock. Goldman Sachs Group Inc. increased their price objective on AveXis from $28.00 to $47.00 and gave the company a “buy” rating in a research note on Friday, May 13th. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research note on Wednesday. Jefferies Group lowered AveXis from a “buy” rating to a “hold” rating and increased their price objective for the company from $39.00 to $42.00 in a research note on Wednesday, June 22nd. They noted that the move was a valuation call. Finally, Chardan Capital initiated coverage on AveXis in a research note on Monday, March 28th. They set a “buy” rating and a $60.00 price objective on the stock. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $43.80.

The firm’s market cap is $803.61 million. The stock has a 50 day moving average price of $40.69 and a 200 day moving average price of $30.45.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.89. On average, equities research analysts predict that AveXis Inc. will post ($4.00) earnings per share for the current year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.